BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World J Clin Cases 2020; 8(17): 3718-3729 [PMID: 32953848 DOI: 10.12998/wjcc.v8.i17.3718]
URL: https://www.wjgnet.com/2307-8960/full/v8/i17/3718.htm
Number Citing Articles
1
Devon J. Boyne, Darren R. Brenner, Alind Gupta, Eric Mackay, Paul Arora, Radek Wasiak, Winson Y Cheung, Miguel A. Hernán. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world dataAnnals of Epidemiology 2023; 78: 28 doi: 10.1016/j.annepidem.2022.12.005
2
Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Giulia Bartolini, Laura Bernardini, Alessandro Passardi, Giovanni Luca Frassineti, Valentina Massa, Alessandro Cucchetti. Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic CancerBiomolecules 2021; 11(6): 780 doi: 10.3390/biom11060780
3
Kwangrok Jung, Suhyun Choi, Hyunjoo Song, Kyuhan Kwak, Soyeon Anh, Jae Hyup Jung, Bomi Kim, Jinwoo Ahn, Jaihwan Kim, Jin-Hyeok Hwang, Jong-chan Lee. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysisTherapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231175441